195 related articles for article (PubMed ID: 34181154)
1. Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review.
Pan T; Mulhern B; Viney R; Norman R; Tran-Duy A; Hanmer J; Devlin N
Qual Life Res; 2022 Jan; 31(1):79-89. PubMed ID: 34181154
[TBL] [Abstract][Full Text] [Related]
2. Comparing and transforming PROMIS utility values to the EQ-5D.
Hartman JD; Craig BM
Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
[TBL] [Abstract][Full Text] [Related]
3. A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample.
Rencz F; Brodszky V; Janssen MF
Value Health; 2023 Jul; 26(7):1045-1056. PubMed ID: 36804583
[TBL] [Abstract][Full Text] [Related]
4. Understanding the measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr.
Mulhern BJ; Pan T; Norman R; Tran-Duy A; Hanmer J; Viney R; Devlin NJ
Qual Life Res; 2023 Nov; 32(11):3147-3160. PubMed ID: 37347395
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of PROPr and EQ-5D-5L Value Sets.
Pan T; Mulhern B; Viney R; Norman R; Hanmer J; Devlin N
Pharmacoeconomics; 2022 Mar; 40(3):297-307. PubMed ID: 34786591
[TBL] [Abstract][Full Text] [Related]
6. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
Thompson NR; Lapin BR; Katzan IL
Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
[TBL] [Abstract][Full Text] [Related]
8. Predicting EQ-5D-5L crosswalk from the PROMIS-29 profile for the United Kingdom, France, and Germany.
Klapproth CP; van Bebber J; Sidey-Gibbons CJ; Valderas JM; Leplege A; Rose M; Fischer F
Health Qual Life Outcomes; 2020 Dec; 18(1):389. PubMed ID: 33334351
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
10. Performance of PROMIS Global-10 to Legacy Instruments in Patients With Lateral Epicondylitis.
Kahan JB; Kassam HF; Nicholson AD; Saad MA; Kovacevic D
Arthroscopy; 2019 Mar; 35(3):770-774. PubMed ID: 30674423
[TBL] [Abstract][Full Text] [Related]
11. Utilities Estimated from PROMIS Scales for Cost-Effectiveness Analyses in Stroke.
Thompson NR; Lapin BR; Katzan IL
Med Decis Making; 2023 Aug; 43(6):704-718. PubMed ID: 37401739
[TBL] [Abstract][Full Text] [Related]
12. Comparison between EQ-5D-5L and PROMIS-10 to evaluate health-related quality of life 3 months after stroke: a cross-sectional multicenter study.
DE Graaf JA; Visser-Meily JM; Schepers VP; Baars A; Kappelle LJ; Passier PE; Wermer MJ; DE Wit DC; Post MW
Eur J Phys Rehabil Med; 2021 Jun; 57(3):337-346. PubMed ID: 33448750
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
15. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
16. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
17. Performance of PROMIS Global-10 Compared With Legacy Instruments for Rotator Cuff Disease.
Nicholson AD; Kassam HF; Pan SD; Berman JE; Blaine TA; Kovacevic D
Am J Sports Med; 2019 Jan; 47(1):181-188. PubMed ID: 30481472
[TBL] [Abstract][Full Text] [Related]
18. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of the EQ-5D in the elderly population: a systematic review of the literature.
Marten O; Brand L; Greiner W
Qual Life Res; 2022 Jun; 31(6):1621-1637. PubMed ID: 34613597
[TBL] [Abstract][Full Text] [Related]
20. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
